Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar;86(3):256-308.
doi: 10.1016/j.jinf.2023.01.004. Epub 2023 Jan 14.

Oseltamivir is protective for in-patient mortality in PCR confirmed influenza B and influenza A(H3N2) infections in an historic cohort of 1,048 patients hospitalised during the 2016-17 and 2017-18 influenza seasons

Mark Reacher  1 , Ben Warne  2 , Neville Q Verlander  3 , Ashley Popay  4 , Lucy Reeve  4 , Nicholas K Jones  2 , Kyriaki Ranellou  5 , Nyaradzai Sithole  2 , Rory Carpenter  2 , Angharad Everden  2 , Elizabeth Jarman  2 , Ali Khalid  6 , Kyle Lam  2 , Chloe Myers  7 , Shuhui Ren  6 , Kathryn J Rolfe  7 , Tommy Sutton  6 , Silvana Christou  2 , Callum Wright  2 , Saher Choudhry  2 , Maria Zambon  8 , Clare Sander  2 , Hongyi Zhang  7 , Hamid Jalal  7
Affiliations

Oseltamivir is protective for in-patient mortality in PCR confirmed influenza B and influenza A(H3N2) infections in an historic cohort of 1,048 patients hospitalised during the 2016-17 and 2017-18 influenza seasons

Mark Reacher et al. J Infect. 2023 Mar.

Abstract

Standard course oseltamivir 75mg two times daily for five days was associated with an 82% reduction of odds of in-patient death (OR 0.18 (0.07,0.51)) compared to no oseltamivir treatment (OR 1.0 Reference) in a final multivariable logistic regression model of a retrospective cohort of PCR confirmed influenza B and influenza A (H3N2) infected patients admitted to a large UK teaching hospital in influenza seasons 2016-17 and 2017-18. No difference of protective odds for standard course oseltamivir was observed between influenza B and influenza A (H3N2) nor between influenza seasons. These observations strongly support clinical guidelines for molecular testing for respiratory viruses on admission to hospital and prompt treatment of confirmed seasonal influenza B and A with oseltamivir 75mg twice daily for five days.

Keywords: Historic Cohort study; Influenza A (H3N2) in-patient mortality; Influenza B; Logistic regression; Multiplex PCR; Multivariable logistic regression; PCR.

PubMed Disclaimer

LinkOut - more resources